With the market capitalization of Aurora Cannabis Inc. currently standing at about $288.03 million, investors are eagerly awaiting this quarter’s results, scheduled for May 10, 2023 – May 15, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share to be -$0.05, which is expected to increase to -$0.04 for fiscal year -$0.28 and then to about -$0.17 by fiscal year 2024. Data indicates that the EPS growth is expected to be 92.70% in 2024, while the next year’s EPS growth is forecast to be 39.30%.
Ontario, Canada’s largest province, only began loosening its COVID-19 restrictions in June, so investors may need to wait a couple of quarters before consumer numbers improve. Canada’s Aurora Cannabis Inc would be open to undertake more merger and acquisition deals in the future to expand its medical cannabis business, the company’s chief executive said on Friday. Marijuana stock investors are keeping focused on the future of the sector. Specifically, most cannabis stock investors are setting a plan that will prepare them for when more consistent trading will t… Even so, Aurora’s shares have lost over 80% of their value in the past 12 months, causing the cannabis titan’s shares to dip below the $1 minimum bid requirement for the Nasdaq Stock Market. Aurora, as a result, may have to either merge with a larger player like Tilray soon or execute yet another reverse split to remain on the Nasdaq.
That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.
Related News ACB
MarketBeat has tracked 6 news articles for Aurora Cannabis this week, compared to 2 articles on an average week. Aurora Cannabis has only been the subject of 1 research reports in the past 90 days. One share of ACB stock can currently be purchased for approximately $0.64. One college student can now replace several coding engineers with AI…
7By Geoffrey Smith Investing.com — U.S. stock markets opened mostly lower on Friday, but were still on track for their highest ever weekly close against a backdrop of an improving… 7By Yasin Ebrahim Investing.com — Cannabis stocks were on fire Thursday as U.S. lawmakers are set to vote on a bill to decriminalize marijuana at the federal level next week,… All that being said, several of these beaten-down cannabis equities were leaking upward to start the year.
Cantor Fitzgerald analyst Pablo Zuanic on Wednesday reiterated an overweight rating on Canada’s Aurora Cannabis Inc. and reduced his price target to $3 a share from $3.12 a share. All in all, cannabis companies north of our border haven’t had an easy time of it. There are scores of them, publicly traded and otherwise, and compared to the U.S., Canada is sparsely populated. So there are a comparatively high number of producers and retailers serving a market that’s quite limited, at the end of the day.
Sell the Farm on These 4 Cannabis Stocks
The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. Sign-up to receive the latest news and ratings for Aurora Cannabis and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Aurora Cannabis is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In the past three months, Aurora Cannabis insiders have not sold or bought any company stock. Represents the company’s profit divided by the outstanding shares of its common stock. That’s why the bottom lines of most Canadian weed players are, more often than not, written in deep red.
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Aurora Cannabis Inc. said Friday it has repurchased $20 million of convertible bonds in a move aimed at reducing its annual interest costs. The Edmonton, Alberta-based cannabis company said it paid $19.2 millin in cash fo… Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. Then again, Aurora is operating in an industry characterized by fierce competition, an unfavorable regulatory environment, high tax burdens, and a vast oversupply of product.
We see that ACB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell. It has been a while since we’ve talked about cannabis stocks, but they’re popping up on investors’ radars on Tuesday.
While a fair number of cannabis users do view the plant as an essential medicine, these economic headwinds are having a negative impact on consumers’ real buying power. That’s bad news for discretionary items like recreational cannabis. The company did particularly badly in the consumer segment, where cannabis net revenue was just CA$18 million — less than half of what the company generated a year earlier. Aurora blamed the poor results primarily on COVID-19 and the impact of lockdowns on distributors and retailers.
The closely-watched AdvisorAurora canabiss stock Pure US Cannabis ETF was trading at $5.32 on Tuesda… The average analyst rating for ACB stock from 14 stock analysts is “Hold”. This means that analysts believe this stock is likely to perform similarly to the overall market.
Stock Price Targets
Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries. The average price target of $4.77 per share implies 244% upside, but I expect these price targets to be adjusted lower as analysts digest the dilution from the recent bought deal offering. Curaleaf has higher revenue and earnings than Aurora Cannabis.
A group of Wall Street veterans, who all used to worked at Merrill Lynch and has a combined experience of more than 230 years, appeared to be mostly bearish about the stock market in the coming months. Consolidation comes with the benefits of aligning supply and demand curves, finding cost-saving synergies, and increasing market share. Tilray, for its part, has already used this business development strategy to markedly increase its market share in Canada through the 2021 merger with Aphria, and then again with its latest acquisition of HEXO. Alex Carchidi has no position in any of the stocks mentioned. Its shares collapsed by more than 70% in the last six months alone, and there’s no indication that the downtrend is reversing. Maintaining independence and editorial freedom is essential to our mission of empowering investor success.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. The company produces, distributes, and sells medical and consumer cannabis products in Canada. 6 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Aurora Cannabis in the last year.
https://forex-world.net/-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. First, if a company is leading off an earnings report by talking about the apparent effectiveness of its cost-cutting effort, it probably has little else to cheer about.
Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis derivative products in Canada and internationally. Its segments include Canadian Cannabis, International Cannabis and Bevo. The Company’s adult-use brand portfolio includes Aurora Drift, San Rafael ’71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark.
Aurora Cannabis repurchases $23 million of convertible notes, backs adjusted EBITDA guidance
On average, they expect the company’s stock price to reach C$2.31 in the next year. This suggests a possible upside of 165.1% from the stock’s current price. View analysts price targets for ACB or view top-rated stocks among Wall Street analysts.
Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. And while it technically could make you richer if a disruptive event like cannabis legalization happens and its stock shoots up, there are better bets to be found elsewhere. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization.
- At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.
- Analysts are projecting the company’s earnings per share to be -$0.05, which is expected to increase to -$0.04 for fiscal year -$0.28 and then to about -$0.17 by fiscal year 2024.
- What’s more, its quarterly revenue declined by 5.9% in the same period, and there’s no indication of it trending back toward its highs in 2019.
- Shareholders, therefore, may welcome a different approach this time around.
- In the past three months, Aurora Cannabis insiders have not sold or bought any company stock.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies. Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review in last seven days.